Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

134 ARTÍCULOS , VIENDO DEL 121 AL 134

Translational proteomics in Alzheimer's disease and related disorders

Ghidoni R, Paterlini A, Benussi L.

Clin Biochem. 2013 Apr;46(6):480-6. doi: 10.1016/j.clinbiochem.2012.10.012. Epub 2012 Oct 23.

Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia

Noel-Storr AH, Flicker L, Ritchie CW, Nguyen GH, Gupta T, Wood P, Walton J, Desai M, Solomon DF, Molena E, Worrall R, Hayen A, Choudhary P, Ladds E, Lanctôt KL, Verhey FR, McCleery JM, Mead GE, Clare L, Fioravanti M, Hyde C, Marcus S, McShane R.

Alzheimers Dement. 2013 May;9(3):e96-e105. doi: 10.1016/j.jalz.2012.01.014. Epub 2012 Oct 27.

Biomarker evidence for uncoupling of amyloid build-up and toxicity in Alzheimer's disease

Zetterberg H, Blennow K.

Alzheimers Dement. 2013 Jul;9(4):459-62. doi: 10.1016/j.jalz.2012.07.002. Epub 2012 Nov 14.

Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease?

Brown BM, Peiffer JJ, Martins RN.

Mol Psychiatry. 2013 Aug;18(8):864-74. doi: 10.1038/mp.2012.162. Epub 2012 Nov 20.

Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?

Mullane K, Williams M.

Biochem Pharmacol. 2013 Feb 1;85(3):289-305. doi: 10.1016/j.bcp.2012.11.014. Epub 2012 Nov 23.

Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder

Jakobsson J, Zetterberg H, Blennow K, Johan Ekman C, Johansson AG, Landén M.

Neuropsychopharmacology. 2013 Mar;38(4):664-72. doi: 10.1038/npp.2012.231. Epub 2012 Nov 6.

Potential blood biomarker for disease severity in the Taiwanese population with Alzheimer's disease

Huang CW, Wang SJ, Wu SJ, Yang CC, Huang MW, Lin CH, Cheng IH.

Am J Alzheimers Dis Other Demen. 2013 Feb;28(1):75-83. doi: 10.1177/1533317512467674. Epub 2012 Dec 10.

Plasma viscosity: is a biomarker for the differential diagnosis of Alzheimer's disease and vascular dementia?

Aras S, Tek I, Varli M, Yalcin A, Cengiz OK, Atmis V, Atli T.

Am J Alzheimers Dis Other Demen. 2013 Feb;28(1):62-8. doi: 10.1177/1533317512467682. Epub 2012 Dec 14.

Research and standardization in Alzheimer's trials: reaching international consensus

Carrillo MC, Rowe CC, Szoeke C, Masters CL, Ames D, O'Meara T, Macaulay SL, Milner A, Ellis KA, Maruff P, Rainey-Smith SR, Martins RN, Bain LJ, Head RJ; NIA/Alzheimer Association and International Working Group.

Alzheimers Dement. 2013 Mar;9(2):160-8. doi: 10.1016/j.jalz.2012.10.006. Epub 2012 Dec 23.

Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia

Olsson B, Hertze J, Ohlsson M, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, Zetterberg H, Blennow K, Hansson O.

J Alzheimers Dis. 2013;34(3):673-9. doi: 10.3233/JAD-121384.

α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment

Korff A, Liu C, Ginghina C, Shi M, Zhang J; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2013;36(4):679-88. doi: 10.3233/JAD-130458.

Molecular biomarkers of neurodegeneration

Höglund K, Salter H.

Expert Rev Mol Diagn. 2013 Nov;13(8):845-61. doi: 10.1586/14737159.2013.850033.

Clinical, biological, and imaging features of monogenic Alzheimer's Disease

Pilotto A, Padovani A, Borroni B.

Biomed Res Int. 2013;2013:689591. doi: 10.1155/2013/689591. Epub 2013 Nov 27.

Neuroimaging biomarkers of neurodegenerative diseases and dementia

Risacher SL, Saykin AJ.

Semin Neurol. 2013 Sep;33(4):386-416. doi: 10.1055/s-0033-1359312. Epub 2013 Nov 14.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias